Return to Clinical Trials Search Results

A Phase III, Randomized, Double-blind Study of Ianalumab (VAY736) Versus Placebo in Addition to First-line Corticosteroids in Primary Immune Thrombocytopenia (VAYHIT1)

Primary Outcome Measures : Time from randomization to treatment failure (TTF) [ Time Frame: Randomization to end of study (up to 39 months after randomization of last patient) ] Time from randomization until platelet count below 30 G/L, need for a rescue treatment or start of a second-line therapy or death.



Recruitment Status

Current Studies